Artelo Biosciences, Inc. (NASDAQ:ARTL – Get Free Report) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 33,300 shares, a decline of 8.3% from the September 15th total of 36,300 shares. Based on an average trading volume of 78,200 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.0% of the company’s stock are sold short.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a report on Wednesday, August 14th.
View Our Latest Stock Analysis on ARTL
Artelo Biosciences Price Performance
Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.10. Analysts anticipate that Artelo Biosciences will post -2.41 earnings per share for the current fiscal year.
Artelo Biosciences Company Profile
Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
Recommended Stories
- Five stocks we like better than Artelo Biosciences
- What is the NASDAQ Stock Exchange?
- NuScale Rockets Higher on Amazon Deal: How High Can It Go?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Why Micron Could Rally All The Way Through Q4
- What Are the U.K. Market Holidays? How to Invest and Trade
- Should Warren Buffett’s Favorite Stock be Yours Too?
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.